Back to Journals » Research Reports in Clinical Cardiology » Volume 3

Emerging options to prevent stroke in atrial fibrillation patients

Authors Silver B

Received 24 October 2011

Accepted for publication 28 November 2011

Published 5 January 2012 Volume 2012:3 Pages 1—9


Review by Single-blind

Peer reviewer comments 4

Brian Silver
Stroke Center, Rhode Island Hospital, Providence, RI, USA

Abstract: Atrial fibrillation is a common condition in the population and increases in prevalence with age. A new method for evaluating stroke risk with atrial fibrillation, called CHA2DS2Vasc, has been developed, as has a novel method for estimating the risk of bleeding, called HAS-BLED. Further, the last decade has seen a dramatic increase in the number of treatment options tested for this condition. These include novel oral anticoagulants such as apixaban, dabigatran, and rivaroxaban, and devices that occlude the left atrial appendage, such as WATCHMAN. This review will compare these new agents with the historical gold standard of warfarin.

Keywords: stroke, atrial fibrillation, treatment

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]